The transactions were executed under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for selling stocks to avoid concerns about insider trading. Following these transactions, Forbes will have a total of 1,383,441 MeiraGTx shares in direct ownership.

The transactions were executed under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for selling stocks to avoid concerns about insider trading. Following these transactions, Forbes will have a total of 1,383,441 MeiraGTx shares in direct ownership.

The transactions were executed under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for selling stocks to avoid concerns about insider trading. Following these transactions, Forbes will have a total of 1,383,441 MeiraGTx shares in direct ownership.

In other breaking news, MeiraGTx Holdings (NASDAQ: ) has achieved significant milestones in its clinical trials and financial development. The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company’s gene therapy candidate AAV2-hAQP1 for the treatment of radiation-induced xerostomia. This regulatory advance demonstrates the therapy’s potential as a one-time treatment for a condition that affects many head and neck cancer patients.

MeiraGTx also reported positive results from its MGT-GAD-025 clinical trial, focused on the treatment of Parkinson’s disease. The trial showed significant improvements in patients with idiopathic Parkinson’s disease. The company plans to work with regulators in the US, Europe, and Japan to begin a Phase 3 study.

Financial analysts show confidence in MeiraGTx’s prospects. Piper Sandler maintained its Overweight rating on the company’s shares, noting potential near-term catalysts and an expected milestone payment of $285 million from a partnership with Johnson & Johnson (NYSE:) . Similarly, RBC Capital maintained an Outperform rating, adjusting its price target for the company.

Additionally, MeiraGTx announced a public offering of 12.5 million ordinary shares at $4 each, seeking to raise $50 million for research and development expenses and clinical trial costs. Chardan Capital Markets initiated coverage of MeiraGTx with a Buy rating, expressing confidence in the company’s gene therapy pipeline. This is one of the new developments that highlight the ongoing financial and research activities of MeiraGTx.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.